Zydus and TLC to commercialize AmphoTLC in India

Zydus and TLC sign a pact to commercialize AmphoTLC in India

Zydus Cadila and Taiwan-based pharma firm TLC have signed a pact to market Liposomal Amphotericin B (AmphoTLC) in India. This news was disclosed on 26 May 2021. 1

The companies have decided to commercialize AmphoTLC (Amphotericin B Liposome for Injection 500 mg) in India. This drug is predominantly used to treat mucormycosis (black fungus).

Per the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus. It will then be commercialized in India by Zydus.

Cadila Healthcare hopes to supply this critical drug to tackle the life-threatening infection in India. TLC’s president has also revealed that the first batch of AmphoTLC will be made available very soon.

Zydus also stated that the CDSCO[1] had approved the NDA[2] of TLC for Amphotericin B Liposome for Injection 50 mg. It has granted permission for immediate importation as per the approved usage and indication.

Mucormycosis, also known as Black Fungus, is a serious fungal infection rapidly rising in India. COVID-19 associated mucormycosis is life-threatening and hence demands immediate treatment.

Read more:

Liposomal Amphotericin B injection or AmphoTLC is used to treat severe systemic fungal infections including mucormycosis.

About mucormycosis: Mucormycosis is a serious but rare fungal infection caused by a group of molds called mucormycetes. Mucormycosis mainly affects people who have health problems or take medicines that lower the body’s immune power.

Abbreviation :

  • 1. Central Drugs Standard Control Organization
  • 2. New Drug Application
Scroll to Top